Kura Oncology, Inc. (NASDAQ:KURA) Q1 2026 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2026 Earnings Call Transcript May 12, 2026Kura Oncology, Inc. beats earnings expectations. Reported EPS is $-0.83, expectations were $-0.88.
Kura Oncology Inc. (KURA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 8,575,422 | $94,072,379 | 1.72% | |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 8,445,769 | $92,650,086 | 2.37% | |
| 3. | Armistice Capital Steven Boyd | 3,678,000 | $40,347,660 | -2% | 0.49% |
| 4. | AQR Capital Management Cliff Asness | 3,126,727 | $34,300,201 | +48% | 0.01% |
| 5. | Prosight Capital Lawrence Hawkins | 2,021,964 | $22,180,945 | -40% | 3.82% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.39 | 100,000 | $1,239,000.00 | 479,194 | 2026-08-24 | Filing | |
| $11.12 | 100,000 | $1,112,000.00 | 379,194 | 2026-08-17 | Filing | |
| $8.20 | 50,000 | $410,145.00 | 100,968 | 2025-09-08 | Filing | |
| $6.64 | 13,494 | $89,623.10 | 50,968 | 2025-08-13 | Filing | |
| $5.85 | 36,506 | $213,578.35 | 37,474 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.89 | 4,345 | $51,663.35 | 169,269 | 2026-08-21 | Filing | |
| $12.63 | 31,487 | $397,680.81 | 195,444 | 2026-08-19 | Filing | |
| $9.82 | 84,929 | $834,283.05 | 182,345 | 2026-06-18 | Filing | |
| $11.00 | 10,000 | $110,000.00 | 173,614 | 2026-05-21 | Filing | |
| $9.21 | 339 | $3,122.19 | 183,614 | 2026-05-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,509,233 | $115,286,283 | 0% | |
| 2. | 5,329,208 | $58,461,412 | 0% | |
| 3. | 3,916,164 | $42,960,319 | 0% | |
| 4. | 2,265,171 | $24,848,925 | 0% | |
| 5. | 2,229,958 | $24,468,022 | 0% |
News See All
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript March 5, 2026Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.92 EPS, expectations were $-0.72.
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the twenty stocks on our list of best biotech stocks is Kura Oncology, Inc.
20 Best Biotech Stocks Under $20 to Buy Now
In this article, we will be taking a look at the 20 Best Biotech Stocks Under $20 to Buy Now. The U.S.
7 Stocks That Were on Jim Cramer’s Radar
Jim Cramer, the host of Mad Money, said on Friday that the data center space may be starting to steady itself after a difficult stretch in the market.
Jim Cramer’s Latest Insights on These 13 Stocks
Jim Cramer, host of Mad Money, discussed the current state of the homebuilders sector on Thursday.
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval
Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2025 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2025 Earnings Call Transcript November 4, 2025Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.84564 EPS, expectations were $-0.57.
Top 10 Stocks Under $10 That Could Triple
On Friday, September 5, the three major averages closed in the red following a weaker-than-expected US jobs report, which caused concerns about a slowing economy.
Hedge Fund Resource Center